RxDoctor Payments Data

Amarinder Garcha

Nephrology · Fresno, CANPI 1770817744

Payments from drug & device makers

$1,335in general payments, 2019–2025

Across 77 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$429
  • AstraZeneca$307
  • Amgen$171
  • Otsuka America Pharmaceutical, Inc.$126
  • Vifor Pharma, Inc.$73
  • Daiichi Sankyo Inc.$67
  • plus $160 from 7 others

What the payments were for

  • Food & beverage$1,27195%
  • Education$645%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,335 in reported general payments places this provider in the 50th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$539,271
Medicare patients
682
Services billed
14,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex162$175,357
VelphoroSucroferric Oxyhydroxide49$122,076
ProsolParenteral Amino Acid 20% No.1348$48,764
LokelmaSodium Zirconium Cyclosilicate37$37,265
Sevelamer Carbonate97$33,091
Cinacalcet Hcl12$11,647
Midodrine Hcl16$6,564
Bumetanide113$5,318
Calcitriol301$5,046
Nifedipine ErNifedipine104$4,405
ClinolipidFat Emulsion/Olive/Soy/Phospho12$3,900
ClinisolParenteral Amino Acid 15% No.529$3,607
Calcium Acetate48$3,444
Potassium Chloride93$3,298
Metolazone23$1,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$429$122,07649 claims
AstraZenecaLokelma$307$37,26537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,341 nephrology providers in California.

Other nephrology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →